SCHEMBL1089141

SCHEMBL1089141

COc1ccc(C(=O)N2CCC(N3CCC(Nc4nccc(N5CCCCCC5)n4)C3)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK12 Q9NYV4 6/20 0.48
CCNK O75909 5/20 0.48
CCNC P24863 1/20 0.46
CDK8 P49336 1/20 0.46
CXCR4 P61073 1/20 0.46
NOS1 P29475 3/20 0.45
NOS2 P35228 3/20 0.45
NOS3 P29474 2/20 0.45
KDM4E B2RXH2 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
EPHX2 P34913 1/20 0.45
CCNA2 P20248 4/20 0.45
CDK2 P24941 4/20 0.45
CDK7 P50613 4/20 0.45
CCNH P51946 4/20 0.45
MNAT1 P51948 4/20 0.45
SLC6A7 Q99884 1/20 0.44
HPGD P15428 1/20 0.43
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1090175 0.96 CDK12 (0.51) CDK12CCNKCCNCCDK8KDM4E
SCHEMBL1090286 0.96 CDK12 (0.49) CDK12CCNKCCNCCDK8CXCR4
SCHEMBL1090729 0.92 CDK12 (0.53) CDK12CCNKCCNCCDK8CXCR4
SCHEMBL1089601 0.91 CCNK (0.50) CDK12CCNKCXCR4KDM4EMBTD1
SCHEMBL1090288 0.90 ALDH1A1 (0.49) CDK12CCNKCCNCCDK8CXCR4
SCHEMBL1090795 0.90 HPGD (0.50) CDK12CCNKCXCR4CCNA2CDK2
SCHEMBL1090838 0.89 CCNC (0.47) CDK12CCNKCCNCCDK8CXCR4
SCHEMBL1089223 0.89 L3MBTL1 (0.53) CDK12CCNKCXCR4KDM4EEPHX2
SCHEMBL1091044 0.89 CXCR4 (0.56) CDK12CCNKCXCR4NOS1NOS2
SCHEMBL1090264 0.88 CDK12 (0.54) CDK12CCNKCCNCCDK8CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CDK12 2526/4885CCNK 793/4885CCNC 529/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CDK12 2526/4885CCNK 793/4885CCNC 529/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CDK12 2526/4885CCNK 793/4885CCNC 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.